Drug intelligence / Profile preview

KY1104

Development stage: Preclinical
Lead developer: KYDES Pharmaceuticals
Modality: Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration: Topical

Overview

KY1104 is a topical microbicide being developed by KYDES Pharmaceuticals for the prevention of HIV infection. Currently in the preclinical stage, the drug is designed for topical application to provide a protective barrier against viral transmission. Its mechanism of action involves the inhibition of viral replication and the reduction of viral integration into the host cell's genome, thereby preventing the establishment of a permanent infection.

Targets

Integrase allosteric pocket (HIV)

Beyond the preview

Go deeper on KY1104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KY1104.

Explore the full profile